Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone561-922-5808
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20.59 million
Profitability
Miscellaneous
Employees45
OptionableNot Optionable
Sensus Healthcare (NASDAQ:SRTS) Frequently Asked Questions
What is Sensus Healthcare's stock symbol?
Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."
How were Sensus Healthcare's earnings last quarter?
Sensus Healthcare Inc (NASDAQ:SRTS) announced its earnings results on Thursday, February, 14th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The company earned $8.08 million during the quarter, compared to analyst estimates of $7.33 million. Sensus Healthcare had a negative net margin of 10.21% and a negative return on equity of 16.98%. View Sensus Healthcare's Earnings History.
When is Sensus Healthcare's next earnings date?
What price target have analysts set for SRTS?
6 analysts have issued 12 month price objectives for Sensus Healthcare's shares. Their predictions range from $5.00 to $14.00. On average, they expect Sensus Healthcare's share price to reach $10.6667 in the next twelve months. This suggests a possible upside of 43.2% from the stock's current price. View Analyst Price Targets for Sensus Healthcare.
What is the consensus analysts' recommendation for Sensus Healthcare?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sensus Healthcare.
Has Sensus Healthcare been receiving favorable news coverage?
News articles about SRTS stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sensus Healthcare earned a news impact score of 1.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the immediate future.
Who are some of Sensus Healthcare's key competitors?
Some companies that are related to Sensus Healthcare include LeMaitre Vascular (LMAT), Antares Pharma (ATRS), Orthopediatrics (KIDS), Inovio Pharmaceuticals (INO), Axonics Modulation Technologies (AXNX), SI-Bone (SIBN), Accuray (ARAY), Pulse Biosciences (PLSE), Utah Medical Products (UTMD), GenMark Diagnostics (GNMK), MiMedx Group (MDXG), Iradimed (IRMD), Neuronetics (STIM), SeaSpine (SPNE) and Vapotherm (VAPO).
Who are Sensus Healthcare's key executives?
Sensus Healthcare's management team includes the folowing people:
- Mr. Joseph C. Sardano, Chairman, CEO & Pres (Age 66)
- Mr. Arthur R. Levine, Chief Financial Officer (Age 61)
- Mr. Kalman Fishman, COO & CTO (Age 48)
- Mr. Michael Sardano, Gen. Counsel, Corp. Sec. and Director of Governance & Regulatory (Age 31)
- Mr. Richard Golin, Exec. VP of International (Age 65)
When did Sensus Healthcare IPO?
(SRTS) raised $20 million in an initial public offering (IPO) on Wednesday, March 30th 2016. The company issued 1,800,000 shares at $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company served as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.
Who are Sensus Healthcare's major shareholders?
Sensus Healthcare's stock is owned by a number of of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.28%), BlackRock Inc. (0.16%) and Northern Trust Corp (0.07%). Company insiders that own Sensus Healthcare stock include Arthur Levine, Joseph C Sardano, Kalman Fishman, Richard Golin and Stephen Brad Cohen. View Institutional Ownership Trends for Sensus Healthcare.
Which institutional investors are buying Sensus Healthcare stock?
How do I buy shares of Sensus Healthcare?
Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sensus Healthcare's stock price today?
One share of SRTS stock can currently be purchased for approximately $7.45.
How big of a company is Sensus Healthcare?
Sensus Healthcare has a market capitalization of $119.80 million and generates $20.59 million in revenue each year. The company earns $-3,710,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Sensus Healthcare employs 45 workers across the globe.
What is Sensus Healthcare's official website?
How can I contact Sensus Healthcare?
Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at 561-922-5808 or via email at [email protected]
MarketBeat Community Rating for Sensus Healthcare (NASDAQ SRTS)
MarketBeat's community ratings are surveys of what our community members think about Sensus Healthcare and other stocks. Vote "Outperform" if you believe SRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
